BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 15148985)

  • 21. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Drug evaluation: new requirements and perspectives].
    Addis A; Rocchi F
    Recenti Prog Med; 2006 Nov; 97(11):618-25. PubMed ID: 17252718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baby doe redux? The Department of Health and Human Services and the Born-Alive Infants Protection Act of 2002: a cautionary note on normative neonatal practice.
    Sayeed SA
    Pediatrics; 2005 Oct; 116(4):e576-85. PubMed ID: 16199687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reorienting the course of medicines policy: actions are bearing fruit.
    Prescrire Int; 2003 Oct; 12(67):192-4. PubMed ID: 14619908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health benefits and health claims of probiotics: bridging science and marketing.
    Rijkers GT; de Vos WM; Brummer RJ; Morelli L; Corthier G; Marteau P
    Br J Nutr; 2011 Nov; 106(9):1291-6. PubMed ID: 21861940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The pharmaceutical industry as a political player.
    Abraham J
    Lancet; 2002 Nov; 360(9344):1498-502. PubMed ID: 12433532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generics market in Greece: the pharmaceutical industry's beliefs.
    Geitona M; Zavras D; Hatzikou M; Kyriopoulos J
    Health Policy; 2006 Nov; 79(1):35-48. PubMed ID: 16386326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The drug industry and research: status in Germany].
    Geursen R
    Zentralbl Chir; 1996; 121(7):603-5. PubMed ID: 8967203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Organisation of clinical research in France: the new missions of inter-regional delegations for clinical research].
    Jaillon P
    Bull Acad Natl Med; 2008 May; 192(5):929-37; discussion 937-9. PubMed ID: 19238783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The advertising of medicinal products to the public in Poland--legislative, ethical, health and social concerns].
    Cianciara D
    Przegl Epidemiol; 2004; 58(3):555-63. PubMed ID: 15730020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. European Generic Medicines Association (EGA)--16th Annual Conference.
    Kennedy B
    IDrugs; 2010 Aug; 13(8):530-3. PubMed ID: 20721822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Update on counterfeit drugs: a growing risk for public health].
    Juillet Y
    Bull Acad Natl Med; 2008 Oct; 192(7):1423-34; discussion 1434-6. PubMed ID: 19445366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmaceutical marketing practices: balancing public health and law enforcement interests; moving beyond regulation-through-litigation.
    Zalesky CD
    J Health Law; 2006; 39(2):235-64. PubMed ID: 17002233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Repackaging drugs in pill-box in France: an illegal activity for pharmacists?].
    Hallouard F; Bourdelin M; Fessi H; Bontemps H
    Ann Pharm Fr; 2011 Jul; 69(4):201-4. PubMed ID: 21840438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spurious and counterfeit drugs: a growing industry in the developing world.
    Gautam CS; Utreja A; Singal GL
    Postgrad Med J; 2009 May; 85(1003):251-6. PubMed ID: 19520877
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Price regulation and generic competition in the pharmaceutical market.
    Dalen DM; Strøm S; Haabeth T
    Eur J Health Econ; 2006 Sep; 7(3):208-14. PubMed ID: 16841230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medicines agencies too often under the influence of drug companies.
    Prescrire Int; 2011 Apr; 20(115):108. PubMed ID: 21648219
    [No Abstract]   [Full Text] [Related]  

  • 39. The patients' and consumers' working party at the European Medicines Agency: a model of interaction between patients, consumers, and medicines regulatory authorities.
    Moulon I; Dedes N
    J Ambul Care Manage; 2010; 33(3):190-7. PubMed ID: 20539145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spending on medicines in Israel in an international context.
    Sax P
    Isr Med Assoc J; 2005 May; 7(5):286-91. PubMed ID: 15909459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.